The MECP2 Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population derived from the Raji B lymphocyte cell line, in which the MECP2 gene has been functionally disrupted. This product provides a heterogeneous pool of cells carrying diverse loss-of-function mutations within the MECP2 locus, enabling robust investigation of MECP2-dependent processes without the constraints of single-clone adaptation. The polyclonal format preserves biological variability and reduces selection bias, making it a versatile tool for studying transcriptional regulation and epigenetic signaling in a lymphoma background. These cells are suitable for a wide range of functional assays, including gene expression analysis, chromatin occupancy studies, and phenotypic screening.
The parental Raji cell line is an Epstein-Barr virus?Cpositive B lymphoblastoid line originally established from a patient with Burkitt lymphoma. As an immortalized B lymphocyte model, Raji cells maintain many features of transformed germinal center B cells and are widely employed in immunological and oncological research. Their robust growth in suspension culture, well-characterized genetic landscape, and susceptibility to genetic manipulation make them an ideal host for CRISPR-mediated knockout modeling. This genetic background is particularly relevant for examining gene functions involved in lymphocyte biology, lymphomagenesis, and the interplay between epigenetic modification and B cell malignancies.
MECP2 encodes a methyl-CpG-binding protein that functions as a transcriptional repressor. It binds to symmetrically methylated CpG dinucleotides and recruits co-repressor complexes containing SIN3A, HDAC1, and HDAC2, leading to histone deacetylation and silencing of downstream targets such as BDNF, DLX5, and GABRB3. MECP2 activity is modulated by upstream regulators including the transcription factors SP1 and CREB, and the microRNA miR-132, and it cooperates with DNA methyltransferases DNMT1 and DNMT3A. Through interactions with NCOR1, SMRT, and heterochromatin protein HP1, MECP2 establishes repressive chromatin states critical for neuronal maturation and also influences gene regulation in B lymphocytes.
In Raji B cells, MECP2-mediated transcriptional repression contributes to the epigenetic landscape that governs gene expression programs relevant to lymphocyte function and transformation. Disruption of MECP2 in this Burkitt lymphoma model permits the dissection of its role in regulating genes potentially involved in cell proliferation, apoptosis, and immune signaling. This polyclonal knockout pool enables researchers to investigate how loss of MECP2 alters chromatin structure and gene expression in a lymphoblastoid background, providing insights into the epigenetic mechanisms that may contribute to B cell malignancies and opening avenues for comparative studies with MECP2-related neurodevelopmental disorders, where gene targets may overlap.
These polyclonal knockout cells are ideally suited for RT-qPCR and Western blotting to measure expression of MECP2 targets (e.g., BDNF, UBE3A), ChIP-qPCR for histone modification analysis, and RNA-seq for transcriptome-wide profiling. Flow cytometry can assess surface markers and viability in drug screening for MECP2 modulators. Functional complementation with variant MECP2 constructs is also feasible. For technical inquiries or custom requests, please contact Ascent Research.
